ProQR Therapeutics N.V.
PRQR
$1.76
-$0.06-3.30%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 61.97% | -22.22% | |||
| Total Other Revenue | -15.54% | -78.47% | |||
| Total Revenue | 61.09% | -24.46% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 61.09% | -24.46% | |||
| SG&A Expenses | 24.22% | -33.29% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.14% | -9.85% | |||
| Operating Income | 19.73% | 5.10% | |||
| Income Before Tax | 19.31% | 6.77% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 19.30% | 6.91% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 19.30% | 6.91% | |||
| EBIT | 19.73% | 5.10% | |||
| EBITDA | 16.77% | 5.54% | |||
| EPS Basic | 19.25% | 6.94% | |||
| Normalized Basic EPS | 19.27% | 6.84% | |||
| EPS Diluted | 19.25% | 10.35% | |||
| Normalized Diluted EPS | 19.27% | 6.84% | |||
| Average Basic Shares Outstanding | 0.01% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.01% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||